Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Tapolca – page 15

245 clinical trials in Tapolca, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Tapolca at a glance
245
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

245 trials in Tapolca

Open in trial search

A study comparing the effectiveness of vorolanib and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyepoint Inc.

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Hyperlipidaemia

Not recruiting

A Study of Enlicitide and Rosuvastatin for Adults With High Cholesterol

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years
  • Substances:Enlicitide decanoate
  • Sponsor:Merck Sharp & Dohme LLC

A Study of XC001 Gene Therapy with Bypass Surgery for Patients with Coronary Artery Disease and Weakened Heart Function at Risk for Incomplete Treatment

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Adenosine
  • Sponsor:Xylocor Therapeutics Inc.

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Dermatitis atopic

Not recruiting

Study of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Qilu Pharmaceutical Co. Ltd.

Rheumatoid arthritis

Not recruiting

Study of lutikizumab and ravagalimab in adults with moderate to severe rheumatoid arthritis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Cardiac failure

Not recruiting

Study on COR-1167 for Patients with Worsening Heart Failure

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:COR-1167 sodium
  • Sponsor:Corteria Pharmaceuticals

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Tapolca

What the registry says about research in the country

01 Respiratory Medicine

Innovative clinical research focusing on Chronic Obstructive Pulmonary Disease (COPD) management through advanced combination therapy approaches. The studies aim to evaluate new treatment options for improving cardiopulmonary outcomes in patients.

  • Triple Therapy Evaluation
  • Cardiopulmonary Outcomes
  • Bronchodilator Treatment

The research examines the comparative effectiveness of combination therapies including budesonide, glycopyrronium, and formoterol in treating COPD, with special attention to severe cardiopulmonary manifestations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.